Compare Stocks: RCUS, EXEL, BMRN, and MDGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.67 -0.9%	$61.88	$49.26 ▼ $70.98	$12.51B	0.24	2.06 million shs	420,218 shs
EXEL Exelixis	$55.57 +1.7%	$54.64	$33.76 ▼ $57.57	$13.76B	0.44	2.66 million shs	592,777 shs
MDGL Madrigal Pharmaceuticals	$538.36 -0.3%	$527.51	$393.61 ▼ $615.00	$12.44B	-1.01	344,699 shs	42,075 shs
RCUS Arcus Biosciences	$29.54 +0.9%	$29.18	$10.55 ▼ $31.74	$3.76B	0.8	1.23 million shs	208,481 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+0.87%	+0.25%	+8.68%	+22.34%	+11.94%
EXEL Exelixis	+0.35%	+0.16%	+3.04%	+12.57%	+46.02%
MDGL Madrigal Pharmaceuticals	+1.17%	+5.48%	+15.56%	+19.25%	+23.34%
RCUS Arcus Biosciences	-0.03%	-3.12%	+3.84%	+19.82%	+176.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.67 -0.9%	$61.88	$49.26 ▼ $70.98	$12.51B	0.24	2.06 million shs	420,218 shs
EXEL Exelixis	$55.57 +1.7%	$54.64	$33.76 ▼ $57.57	$13.76B	0.44	2.66 million shs	592,777 shs
MDGL Madrigal Pharmaceuticals	$538.36 -0.3%	$527.51	$393.61 ▼ $615.00	$12.44B	-1.01	344,699 shs	42,075 shs
RCUS Arcus Biosciences	$29.54 +0.9%	$29.18	$10.55 ▼ $31.74	$3.76B	0.8	1.23 million shs	208,481 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+0.87%	+0.25%	+8.68%	+22.34%	+11.94%
EXEL Exelixis	+0.35%	+0.16%	+3.04%	+12.57%	+46.02%
MDGL Madrigal Pharmaceuticals	+1.17%	+5.48%	+15.56%	+19.25%	+23.34%
RCUS Arcus Biosciences	-0.03%	-3.12%	+3.84%	+19.82%	+176.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.92	36.50% Upside
EXEL Exelixis	2.30	Hold	$50.07	-9.94% Downside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.64	29.08% Upside
RCUS Arcus Biosciences	2.58	Moderate Buy	$37.80	28.29% Upside

Current Analyst Ratings Breakdown

Latest RCUS, EXEL, BMRN, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	BMRN BioMarin Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $105.00
8/31/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$59.00 ➝ $60.00
8/26/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$88.00
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$60.00 ➝ $59.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/17/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $88.00
8/17/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$105.00 ➝ $111.00
8/11/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)

(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.91	$2.87 per share	22.66	$31.68 per share	2.06
EXEL Exelixis	$2.32B	5.94	$3.09 per share	17.99	$8.06 per share	6.90
MDGL Madrigal Pharmaceuticals	$958.40M	13.06	N/A	N/A	$26.54 per share	20.42
RCUS Arcus Biosciences	$247M	15.19	N/A	N/A	$5.84 per share	5.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	176.57	12.06	0.46	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	17.46	14.98	1.62	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	97.67	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)

Latest RCUS, EXEL, BMRN, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
RCUS Arcus Biosciences	0.22	3.82	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
MDGL Madrigal Pharmaceuticals	98.50%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
MDGL Madrigal Pharmaceuticals	17.60%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
MDGL Madrigal Pharmaceuticals	90	23.10 million	19.04 million	Optionable
RCUS Arcus Biosciences	500	127.33 million	117.66 million	Optionable

RCUS, EXEL, BMRN, and MDGL Headlines

Recent News About These Companies

Arcus Biosciences, Inc. $RCUS Position Decreased by Montanova Capital LLC

September 1 at 5:52 AM | marketbeat.com

Wellington Management Group LLP Sells 194,068 Shares of Arcus Biosciences, Inc. $RCUS

September 1 at 5:11 AM | marketbeat.com

Bank of New York Mellon Corp Invests $16.74 Million in Arcus Biosciences, Inc. $RCUS

September 1 at 3:27 AM | marketbeat.com

Man Group plc Acquires New Shares in Arcus Biosciences, Inc. $RCUS

August 31 at 5:12 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Arcus Biosciences, Inc. $RCUS

August 27, 2026 | marketbeat.com

Deutsche Bank AG Invests $2.92 Million in Arcus Biosciences, Inc. $RCUS

August 27, 2026 | marketbeat.com

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

August 26, 2026 | businesswire.com

Odyssean LLC Makes New Investment in Arcus Biosciences, Inc. $RCUS

August 26, 2026 | marketbeat.com

PDT Partners LLC Buys New Stake in Arcus Biosciences, Inc. $RCUS

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Purchases New Position in Arcus Biosciences, Inc. $RCUS

August 25, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,827 Shares

August 25, 2026 | insidertrades.com

BlackRock Inc. Makes New $506.11 Million Investment in Arcus Biosciences, Inc. $RCUS

August 25, 2026 | marketbeat.com

Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 2,827 Shares of Stock

August 24, 2026 | marketbeat.com

Bank of America Corp DE Decreases Position in Arcus Biosciences, Inc. $RCUS

August 22, 2026 | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 22, 2026 | americanbankingnews.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Moderate Buy" by Analysts

August 22, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

August 19, 2026 | prnewswire.com

Arcus Biosciences Bets Big on Casdatifan Pipeline

August 19, 2026 | theglobeandmail.com

Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS

August 19, 2026 | marketbeat.com

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

August 13, 2026 | insidermonkey.com

Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RCUS, EXEL, BMRN, and MDGL Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$64.67 -0.56 (-0.85%)

As of 12:06 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$55.57 +0.93 (+1.70%)

As of 12:06 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$538.36 -1.68 (-0.31%)

As of 12:06 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Arcus Biosciences NYSE:RCUS

$29.54 +0.26 (+0.89%)

As of 12:06 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, EXEL, BMRN, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, EXEL, BMRN, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, EXEL, BMRN, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCUS, EXEL, BMRN, and MDGL Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Madrigal Pharmaceuticals NASDAQ:MDGL

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, EXEL, BMRN, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, EXEL, BMRN, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, EXEL, BMRN, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCUS, EXEL, BMRN, and MDGL Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Madrigal Pharmaceuticals NASDAQ:MDGL

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools